Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
FYI: Shares of Intercept Pharmaceuticals (NasdaqGS: ICPT) surged nearly 29% during Thursday’s after-hours session after the company investigational product obeticholic acid (OCA) landed “breakthrough therapy designation” from the U.S. Food and Drug Administration (FDA) for the treatment of patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis, according to a statement. Regards, Ted http://www.etftrends.com/2015/01/this-etf-should-like-the-intercept-pharma-news/
